Zanubrutinib vs Ibrutinib in Symptomatic WM: Final Analysis From the ASPEN Study

Key Findings

• ●At 44.4-month follow-up, VGPR+CR: 36.3% zanubrutinib vs 25.3% ibrutinib
• ●Ibrutinib had higher rates of atrial fibrillation (23.5% vs 7.9%), hypertension, diarrhea
• ●Zanubrutinib confirmed as having improved long-term safety profile

Referenced in (1 disease)